News Medical

Test document

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
ascopubs.org

A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy

Does one person provide it all? Defining the social support of women with cancer Pts with adverse events - n (%) 46 (79) 49 (88) 95 (83) Pts with serious adverse events - n (%) 18 (31) 21 (38) 39 (34) ...
Reuters

Amgen study shows no increased Aranesp death risk

NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
ascopubs.org

Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy ...

Prechemotherapy hemoglobin (Hgb) and cognitive impairment among breast cancer patients This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a full text ...
Nature

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Patients with low or intermediate-1 (int-1) International Prognostic Scoring System (IPSS) risk myelodysplastic syndromes (MDS) have a median survival of 5.7 and 3.5 years, respectively, when treated ...